Vimarsana
Biggest News Aggregation in the World

Page 2 - Brian Goff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Brian Goff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Brian Goff Today - Breaking & Trending Today

Agios Pharmaceuticals (NASDAQ:AGIO) Issues Earnings Results, Beats Estimates By $0.19 EPS - Vimarsana News

Agios Pharmaceuticals (NASDAQ:AGIO) Issues Earnings Results, Beats Estimates By $0.19 EPS

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company had […]

Source: wkrb13.com
Agios Pharmaceuticals (NASDAQ:AGIO) Announces Quarterly Earnings Results - Vimarsana News

Agios Pharmaceuticals (NASDAQ:AGIO) Announces Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.19, Briefing.com reports. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals […]

Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results - Vimarsana News

Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) EPS for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company had revenue of […]

The Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00 - Vimarsana News

The Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) had its price target hoisted by equities researchers at The Goldman Sachs Group from $29.00 to $33.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target indicates a potential downside of […]

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report - Vimarsana News

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

09.04.2024 - – Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals ...